June 8, 2006. Clinical trials are a major source of information on the short-term risks of silicone breast implants. In clinical trials, the goal is to follow women prospectively to determine what complications and health problems occur, and to compare that to a control group.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Statement on FDA ‘Approvable’ Letter for Breast Implant Manufacturer
September 24, 2005. The Food and Drug Administration (FDA) issued an “approvable letter” to Inamed Corporation for their silicone gel breast implants, and NCHR finds this unacceptable.
Read More »NCHR Statement on FDA Breast Implant Decision
July 28, 2005. The Food and Drug Administration (FDA) has issued an “approvable letter” to Mentor regarding their silicone gel breast implants. This does not mean that these implants have been approved, but it is a warning sign that corporate pressure on the FDA has once again put women’s health at risk.
Read More »NCHR Statement on Protecting Patients from Long-Term Risks
February 17, 2005. When Americans take medication, they don’t expect to have to read the studies that have been conducted on the product.
Read More »NCHR Testimony to FDA Regarding Suicide and the Use of Antidepressants by Children
September 13, 2004. The widespread use of antidepressant drugs by children and youth in the United States is cause for great concern.
Read More »